- Home
- ECX vs TYRA Comparison
ECX vs TYRA Comparison
Compare ECX & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECX
- TYRA
- Stock Information
- Founded
- ECX 2017
- TYRA 2018
- Country
- ECX China
- TYRA United States
- Employees
- ECX N/A
- TYRA N/A
- Industry
- ECX EDP Services
- TYRA Biotechnology: Pharmaceutical Preparations
- Sector
- ECX Technology
- TYRA Health Care
- Exchange
- ECX Nasdaq
- TYRA Nasdaq
- Market Cap
- ECX 589.5M
- TYRA 576.6M
- IPO Year
- ECX N/A
- TYRA 2021
- Fundamental
- Price
- ECX $1.75
- TYRA $9.23
- Analyst Decision
- ECX Strong Buy
- TYRA Strong Buy
- Analyst Count
- ECX 1
- TYRA 7
- Target Price
- ECX $3.20
- TYRA $30.86
- AVG Volume (30 Days)
- ECX 1.5M
- TYRA 376.4K
- Earning Date
- ECX 08-07-2025
- TYRA 08-06-2025
- Dividend Yield
- ECX N/A
- TYRA N/A
- EPS Growth
- ECX N/A
- TYRA N/A
- EPS
- ECX N/A
- TYRA N/A
- Revenue
- ECX $805,604,079.00
- TYRA N/A
- Revenue This Year
- ECX $26.72
- TYRA N/A
- Revenue Next Year
- ECX $30.34
- TYRA N/A
- P/E Ratio
- ECX N/A
- TYRA N/A
- Revenue Growth
- ECX 19.98
- TYRA N/A
- 52 Week Low
- ECX $0.76
- TYRA $6.42
- 52 Week High
- ECX $3.25
- TYRA $29.60
- Technical
- Relative Strength Index (RSI)
- ECX 55.70
- TYRA 41.84
- Support Level
- ECX $1.57
- TYRA $10.11
- Resistance Level
- ECX $1.96
- TYRA $10.68
- Average True Range (ATR)
- ECX 0.12
- TYRA 0.79
- MACD
- ECX 0.01
- TYRA -0.08
- Stochastic Oscillator
- ECX 52.27
- TYRA 7.05
About ECX ECARX Holdings Inc. Ordinary shares
ECARX Holdings Inc is engaged in the sales of system-on-chip core modules, automotive computing platform products, and software stacks as well as the provision of research and development services in the People's Republic of China. The company's core products include infotainment head units, digital cockpits, vehicle chip-set solutions, a core operating system, and an integrated software stack. Beyond this, ECARX is developing a full-stack automotive computing platform. It is engaged in automotive intelligence and networking.
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.